+

WO2003083105A1 - Traitement et prevention de l'angiostenose - Google Patents

Traitement et prevention de l'angiostenose Download PDF

Info

Publication number
WO2003083105A1
WO2003083105A1 PCT/JP2002/003048 JP0203048W WO03083105A1 WO 2003083105 A1 WO2003083105 A1 WO 2003083105A1 JP 0203048 W JP0203048 W JP 0203048W WO 03083105 A1 WO03083105 A1 WO 03083105A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
cells
smooth muscle
seq
virus
Prior art date
Application number
PCT/JP2002/003048
Other languages
English (en)
Japanese (ja)
Inventor
Shin-Ichi Miyatake
Original Assignee
Medicalseed Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicalseed Co., Ltd. filed Critical Medicalseed Co., Ltd.
Priority to PCT/JP2002/003048 priority Critical patent/WO2003083105A1/fr
Priority to JP2003580555A priority patent/JPWO2003083122A1/ja
Priority to PCT/JP2003/003809 priority patent/WO2003083122A1/fr
Publication of WO2003083105A1 publication Critical patent/WO2003083105A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • mice with fl injuries were killed at a given B number.
  • the plate was washed with PBS containing% DMSO.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des moyens de traitement et de prévention de l'angiosténose, à savoir un vecteur de réplication à expression spécifique en fonction du muscle lisse vasculaire, qui n'agit pas sur les cellules adultes normales se caractérisant par le fait d'avoir le domaine régulateur d'initiation de transcription d'un gène exprimé spécifiquement dans le muscle lisse vasculaire intégré en amont d'un gène précis; elle concerne également des compositions médicales les contenant destinées au traitement et à la prévention de l'angiosténose; ainsi qu'un procédé associé.
PCT/JP2002/003048 2002-03-28 2002-03-28 Traitement et prevention de l'angiostenose WO2003083105A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/JP2002/003048 WO2003083105A1 (fr) 2002-03-28 2002-03-28 Traitement et prevention de l'angiostenose
JP2003580555A JPWO2003083122A1 (ja) 2002-03-28 2003-03-27 血管狭窄の処置および予防
PCT/JP2003/003809 WO2003083122A1 (fr) 2002-03-28 2003-03-27 Traitement et prevention de l'angiostenose

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2002/003048 WO2003083105A1 (fr) 2002-03-28 2002-03-28 Traitement et prevention de l'angiostenose

Publications (1)

Publication Number Publication Date
WO2003083105A1 true WO2003083105A1 (fr) 2003-10-09

Family

ID=28470384

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2002/003048 WO2003083105A1 (fr) 2002-03-28 2002-03-28 Traitement et prevention de l'angiostenose
PCT/JP2003/003809 WO2003083122A1 (fr) 2002-03-28 2003-03-27 Traitement et prevention de l'angiostenose

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/003809 WO2003083122A1 (fr) 2002-03-28 2003-03-27 Traitement et prevention de l'angiostenose

Country Status (2)

Country Link
JP (1) JPWO2003083122A1 (fr)
WO (2) WO2003083105A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009090933A1 (fr) * 2008-01-16 2009-07-23 Japan Science And Technology Agency Virus se développant dans des cellules hypoxiques ou vecteur viral exprimant un gène dans celles-ci

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009010A1 (fr) * 1993-09-29 1995-04-06 Kirin Beer Kabushiki Kaisha Medicament contre l'arteriosclerose
WO1996005321A1 (fr) * 1994-08-17 1996-02-22 Rhone-Poulenc Rorer S.A. Therapie genique de la restenose au moyen de vecteur adenovial
WO1997035974A1 (fr) * 1996-03-26 1997-10-02 Institut Pasteur Sequences en amont du gene sm22, vecteurs les contenant et leurs utilisations therapeutiques, notamment dans le traitement des maladies vasculaires

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
EP2324829A1 (fr) * 1993-01-28 2011-05-25 Boston Scientific Limited Inhibiteur therapeutique de cellules de muscles
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
JP2002335965A (ja) * 2001-05-14 2002-11-26 Japan Science & Technology Corp 細胞特異的発現複製ベクター

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009010A1 (fr) * 1993-09-29 1995-04-06 Kirin Beer Kabushiki Kaisha Medicament contre l'arteriosclerose
WO1996005321A1 (fr) * 1994-08-17 1996-02-22 Rhone-Poulenc Rorer S.A. Therapie genique de la restenose au moyen de vecteur adenovial
WO1997035974A1 (fr) * 1996-03-26 1997-10-02 Institut Pasteur Sequences en amont du gene sm22, vecteurs les contenant et leurs utilisations therapeutiques, notamment dans le traitement des maladies vasculaires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hisako YAMAMURA et al.: "Identification of the Transcriptional Regulatory Sequences of Human Calponin Promoter and Their Use in Targeting a Conditionally Replicating Herpes Vector to Malignant Human Soft Tissue and Bone Tumors.", Cancer Research, 15 May, 2000 (15.05.00), Vol.61, pages 3969 to 3977 *

Also Published As

Publication number Publication date
WO2003083122A1 (fr) 2003-10-09
JPWO2003083122A1 (ja) 2005-08-04

Similar Documents

Publication Publication Date Title
JP3778930B2 (ja) 動脈平滑筋細胞増殖の抑制
US7033750B2 (en) Recombinant P53 adenovirus methods and compositions
US5652224A (en) Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5880102A (en) Adenoviral vector system
US8709812B2 (en) Drug comprising as the active ingredient proliferative vector containing survivin promoter
EP4107257A1 (fr) Particule de vecteur viral à base d'aav2 pour thérapie génique
JP2002335965A (ja) 細胞特異的発現複製ベクター
JP2000157289A (ja) 平滑筋細胞および／または内皮細胞への組織向性を与えられた遺伝子送達ベクタ―
US7662795B2 (en) Enhancement of adenoviral oncolytic activity by modification of the E1A gene product
AU2021371806B2 (en) Mesenchymal stem cells that enable tumor targeting improvement and virus mass-production
WO2003083105A1 (fr) Traitement et prevention de l'angiostenose
Peng et al. Construction of recombinant adeno-associated virus vector containing the rat preproinsulin II gene
US7785870B2 (en) Cell-specific expression/replication vector
US20050271622A1 (en) Construct of tumor-selective recombinant adenovirus, method for preparing the same and use thereof
US6413943B1 (en) Methods and reagents for inhibiting proliferation of smooth muscle cells
US20030036524A1 (en) Method of sensitising endothelial cells to prodrugs
CN114438128A (zh) 一种增强型溶瘤腺病毒及其应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载